Evidence map›Paper›PMID 37872620›Full record

ArticleBiomaterials research2023

GM-CSF augmented the photothermal immunotherapeutic outcome of self-driving gold nanoparticles against a mouse CT-26 colon tumor model.

Jie Dai, Jianmei Li, Yuqin Zhang, Qian Wen, Yun Lu, Yu Fan, Fancai Zeng, Zhiyong Qian, Yan Zhang, Shaozhi Fu

Open access · goldAbstract read
In one paragraph

Article in Biomaterials research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jie Dai *Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China.
Jianmei Li *Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China.
Yuqin Zhang *Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China.
Qian WenDepartment of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China.
Yun LuDepartment of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China.
Yu FanDepartment of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China.
Fancai ZengLaboratory of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China.
Zhiyong QianState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, Sichuan, P.R. China.
Yan ZhangDepartment of Oncology, the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China. 113804562@qq.com.
Shaozhi FuDepartment of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P.R. China. shaozhifu513@163.com.ORCID http://orcid.org/0000-0002-8666-4304
Affiliated Hospital of Southwest Medical University · CNSouthwest Medical University · CNSichuan University · CN

Funding

Sichuan Science and Technology Program 2022YFS0623
6 · The paper itself

Abstract

backgroundHypoxia is a frequent characteristic observed in solid tumors and is strongly associated with tumor metastasis, angiogenesis, and drug resistance. While the vasculature of hypoxic tumor tissues poses obstacles to the efficient administration of conventional drugs, it may prove advantageous in sustaining hyperthermia. Photothermal therapy (PTT) offers a promising treatment strategy that utilizes the activation of photosensitizers to produce heat, thus facilitating the selective ablation of tumor tissues.

methodTo enhance the accumulation of photothermal agents in tumor tissue and improve the effectiveness of PTT, we developed a self-propelled hybrid called Bif@PAu-NPs. This hybrid consists of polydopamine (PDA)-coated gold nanoparticles (Au-NPs) loaded onto the anaerobic Bifidobacterium infantis (Bif).

resultsThe Bif@PAu-NPs actively aggregated at the tumor site because the ability of Bif can target hypoxic regions, and PAu-NPs achieved precise PTT due to their high photothermal conversion efficiency (η = 67.8%). The tumor tissues were ablated by PTT, resulting in the release of antigens through immunogenic cell death (ICD), which stimulates an immune response. The inclusion of GM-CSF enhanced the immune response by recruiting dendritic cells and initiating long-term anti-tumor immunity.

conclusionThe Bif@PAu-NPs hybrid effectively suppressed the growth of both primary tumors and re-challenged tumors. The utilization Bif@PAu-NPs in conjunction with GM-SCF exhibits great potential as a photothermal-immunotherapeutic strategy for precisely treating solid tumors. In this study, the bacterial Bif@PAu-NPs biohybrid is exploited the self-driving ability of anaerobic Bifidobacterium infantis to deliver polydopamine-modified gold nanoparticles to hypoxic region of tumor. Under irradiation with 808 nm NIR laser, the hybrid exerts precise photothermal therapy to stimulate the immune response, which is further enhanced by GM-CSF, leading to recruitment of dendritic cells and initiation of a long-term anti-tumor immunity remember to prevent tumor recurrence.

Indexed as

Anaerobic bacteriaColorectal cancerGM-CSFGold nanoparticelsImmunotherapyPhotothermal therapy

Identifiers

PMID37872620
PMCPMC10594909
OpenAlexW4387880571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.